A detailed history of Beirne Wealth Consulting Services, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Beirne Wealth Consulting Services, LLC holds 302,800 shares of ALT stock, worth $2.29 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares
302,800
Previous 277,800 9.0%
Holding current value
$2.29 Million
Previous $1.85 Billion 0.64%
% of portfolio
0.65%
Previous 0.74%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$5.5 - $8.1 $137,500 - $202,500
25,000 Added 9.0%
302,800 $1.86 Billion
Q2 2024

Aug 12, 2024

BUY
$5.91 - $10.23 $29,550 - $51,150
5,000 Added 1.83%
277,800 $1.85 Billion
Q1 2024

May 13, 2024

SELL
$8.22 - $13.81 $254,820 - $428,110
-31,000 Reduced 10.2%
272,800 $2.78 Billion
Q4 2023

Feb 06, 2024

BUY
$2.14 - $11.62 $116,373 - $631,895
54,380 Added 21.8%
303,800 $3.42 Billion
Q1 2023

May 10, 2023

BUY
$4.19 - $16.83 $51,956 - $208,691
12,400 Added 5.23%
249,420 $1.05 Billion
Q4 2022

Feb 08, 2023

SELL
$8.74 - $16.45 $400,292 - $753,410
-45,800 Reduced 16.19%
237,020 $3.9 Million
Q3 2022

Nov 07, 2022

SELL
$10.67 - $22.41 $19,494 - $40,943
-1,827 Reduced 0.64%
282,820 $3.61 Million
Q2 2022

Jul 13, 2022

BUY
$3.94 - $11.77 $397,179 - $1.19 Million
100,807 Added 54.83%
284,647 $3.33 Million
Q1 2022

May 10, 2022

BUY
$5.9 - $9.45 $277,300 - $444,149
47,000 Added 34.35%
183,840 $1.12 Million
Q4 2021

Feb 03, 2022

BUY
$8.69 - $12.48 $42,581 - $61,152
4,900 Added 3.71%
136,840 $1.26 Million
Q3 2021

Nov 09, 2021

SELL
$8.43 - $16.81 $15,426 - $30,762
-1,830 Reduced 1.37%
131,940 $1.49 Million
Q2 2021

Aug 10, 2021

BUY
$9.85 - $16.46 $206,850 - $345,660
21,000 Added 18.62%
133,770 $1.32 Million
Q1 2021

May 17, 2021

BUY
$12.71 - $24.31 $464,486 - $888,408
36,545 Added 47.94%
112,770 $1.59 Million
Q4 2020

Feb 03, 2021

BUY
$7.84 - $14.22 $597,604 - $1.08 Million
76,225 New
76,225 $860,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $370M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Beirne Wealth Consulting Services, LLC Portfolio

Follow Beirne Wealth Consulting Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Beirne Wealth Consulting Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Beirne Wealth Consulting Services, LLC with notifications on news.